At a Glance
- Company: UK government / Department for Science, Innovation and Technology
- Location: United Kingdom
- Deal value: £1.5bn ring‑fenced life‑sciences R&D over four years
- Focus area: Life‑sciences research, health data, clinical trials, pharma growth
- Next steps: Launch Health Data Research Service; implement faster trial timelines; progress “landmark” US pharma deal
What happened?
In a speech to the BioIndustry Association, Science Secretary Liz Kendall confirmed a dedicated, ring‑fenced £1.5 billion budget for life‑sciences R&D to be invested via UK Research and Innovation over the next four years. The announcement forms part of a wider push to make the UK the leading life‑sciences economy in Europe by 2030.
Why does it matter?
Ring‑fenced multi‑year funding gives universities, research institutes and industry greater certainty to plan long‑term programmes, from discovery biology to translational medicine. Coupled with new health‑data and clinical‑trials reforms, the package is positioned as a growth engine for high‑value jobs, inward investment and improved health outcomes.
Who’s behind it?
The measures are led by the Department for Science, Innovation and Technology and delivered largely through UKRI, alongside NIHR and other research funders. Kendall highlighted the MRC Laboratory of Molecular Biology in Cambridge as an exemplar, confirming a 10‑year funding settlement starting at around £50 million a year in this Spending Review period.
How was it achieved?
The life‑sciences budget sits within a broader record R&D package, including more than £38 billion for UKRI across disciplines. The government’s Life Sciences Sector Plan commits over £2 billion to the sector and backs specific initiatives such as the Life Sciences Innovative Manufacturing Fund and targeted AI and genomics investments.
What’s next?
Kendall set out three near‑term pillars: a new Health Data Research Service as a single secure access point for national‑scale health data, substantial reductions in commercial clinical trial start‑up times, and a “landmark” pharma deal with the U.S. to attract investment and trials. Further detail on the US partnership and HDRS implementation is expected as the sector plan is rolled out.
What are people saying?
Kendall described the £1.5 billion allocation as the “dedicated budget for life sciences” that will underpin the UK’s ambition to be Europe’s top life‑sciences economy. Commentators note that long‑term funding commitments and streamlined data access are central asks from industry to unlock private‑sector investment.